Serum IL-17A in newly diagnosed treatment-naive patients with ulcerative colitis reflects clinical disease severity and predicts the course of disease

Inflammatory Bowel Diseases

Volumn 19, Issue 11, 2013, Pages 2433-2439

  Öhman, Lena ^a   Dahlén, Rahil ^a   Isaksson, Stefan ^a   Sjöling, Åsa ^a   Wick, Mary Jo ^a   Sjövall, Henrik ^a   Oudenhove, Lukas Van ^b   Simrén, Magnus ^a   Strid, Hans ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b UNIVERSITY OF LEUVEN   (Belgium)

Author keywords

Disease course; Disease severity; IBD; IL 17A; Ulcerative colitis

Indexed keywords

CALGRANULIN; GAMMA INTERFERON; INTERLEUKIN 17; MESSENGER RNA;

ADULT; ARTICLE; DISEASE COURSE; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PREDICTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; REAL TIME POLYMERASE CHAIN REACTION; RECTUM BIOPSY; SCORING SYSTEM; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; CASE-CONTROL STUDIES; COLITIS, ULCERATIVE; CROSS-SECTIONAL STUDIES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-13; INTERLEUKIN-17; INTESTINAL MUCOSA; MALE; PROGNOSIS; PROSPECTIVE STUDIES; SEVERITY OF ILLNESS INDEX;

EID: 84888241040     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0b013e3182a563cb     Document Type: Article

References (19)

1. DInca R, Dal Pont E, Di Leo V, et al. Can calprotectin predict relapse risk in inflammatory bowel disease Am J Gastroenterol. 2008;103: 2007-2014.
2. Lasson A SM, Stotzer PO, Isaksson S, et al. Faecal calprotectin levels predict the clinical course in patients with new onset of ulcerative colitis. Inflamm Bowel Dis. 2013;19:576-581.
3. Yamamoto T, Umegae S, Kitagawa T, et al. Systemic and local cytokine production in quiescent ulcerative colitis and its relationship to future relapse: A prospective pilot study. Inflamm Bowel Dis. 2005;11:589-596.
4. Ruffolo C, Scarpa M, Faggian D, et al. Cytokine network in rectal mucosa in perianal Crohns disease: relations with inflammatory parameters and need for surgery. Inflamm Bowel Dis. 2008;14:1406-1412.
5. Louis E, Belaiche J, van Kemseke C, et al. A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohns disease. Eur J Gastroenterol Hepatol. 1997;9:939-944.
6. Fuss IJ, Heller F, Boirivant M, et al. Nonclassical CD1d-restricted NK T cells that produce IL-13 characterize an atypical Th2 response in ulcerative colitis. J Clin Invest. 2004;113:1490-1497.
7. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohns disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol. 1996;157:1261-1270.
8. Niessner M, Volk BA. Altered Th1/Th2 cytokine profiles in the intestinal mucosa of patients with inflammatory bowel disease as assessed by quantitative reversed transcribed polymerase chain reaction (RT-PCR). Clin Exp Immunol. 1995;101:428-435.
9. Olsen T, Goll R, Cui G, et al. Tissue levels of tumor necrosis factor-alpha correlates with grade of inflammation in untreated ulcerative colitis. Scand J Gastroenterol. 2007;42:1312-1320.
10. Olsen T, Rismo R, Cui G, et al. TH1 and TH17 interactions in untreated inflamed mucosa of inflammatory bowel disease, and their potential to mediate the inflammation. Cytokine. 2011;56:633-640.
11. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohns disease. Gut. 2008; 57:1682-1689.
12. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-434.
13. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med. 1987;317:1625-1629.
14. Satsangi J, Silverberg MS, Vermeire S, et al. The Montreal classification of inflammatory bowel disease: controversies, consensus, and implications. Gut. 2006;55:749-753.
15. Ajdukovic J, Tonkic A, Salamunic I, et al. Interleukins IL-33 and IL-17/IL-17A in patients with ulcerative colitis. Hepatogastroenterology. 2010; 57:1442-1444.
16. Zheng ZD, Wan XQ, Liu LY. Serum contents of IL-23 and IL-17 in the patients with ulcerative colitis and the clinical significance [Article in Chinese]. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2011;27:203-206.
17. Magro F, Rodrigues A, Vieira AI, et al. Review of the disease course among adult ulcerative colitis population-based longitudinal cohorts. Inflamm Bowel Dis. 2012;18:573-583.
18. Fujino S, Andoh A, Bamba S, et al. Increased expression of interleukin 17 in inflammatory bowel disease. Gut. 2003;52:65-70.
19. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629-1636.